問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of General Surgery

Division of Hematology & Oncology

更新時間：2023-09-19

黃俊升Huang, Chiun-Sheng
  • Principal Investigator
  • Clinical Trial Experience (year) 23 years 9 個月

Recruiting Trial

46Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

黃俊升

List

103Cases

2014-07-31 - 2020-12-25

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2014-06-01 - 2018-09-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2019-01-01 - 2026-06-30

Phase III

A Phase III Multi-center, Randomized, Open-label Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative Early Breast Cancer (New Adjuvant TriAl With Ribociclib [LEE011]: NATALEE)

  • Condition/Disease

    Hormone Receptor-positive, HER2-negative Early Breast Cancer

  • Test Drug

    KISQALI

Participate Sites
9Sites

Recruiting9Sites

2016-06-01 - 2025-05-31

IIT

Phase III

Neo-Adjuvant study with the PDL1-directed antibody in Triple Negative Locally Advanced Breast Cancer undergoing treatment with nabpaclitaxel and carboplatin

  • Condition/Disease

    Triple Negative Locally Advanced Breast Cancer

  • Test Drug

    atezolizumab (MPDL3280A)

Participate Sites
7Sites

Terminated5Sites

曾令民
Taipei Veterans General Hospital

Division of General Surgery

侯明鋒
Kaohsiung Municipal Gangshan Hospital

未分科

2019-07-01 - 2021-12-23

Phase III

A Phase III Randomized, Double-Blind, Neoadjuvant Study of Hormonal Therapy Plus Palbociclib Versus Hormonal Therapy Plus Placebo in Women With Operable, Hormone Sensitive and HER2-Negative Primary Breast Cancer

  • Condition/Disease

    Primary Breast Cancer

  • Test Drug

    Ibrance

Participate Sites
4Sites

Recruiting3Sites

Terminated1Sites

2014-07-01 - 2020-03-01

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2014-12-01 - 2018-11-30

Phase III

A Phase 3, Double-Blind, Randomized, Parallel-Group, Active-Controlled Study to Compare the Efficacy and Safety of CT-P6 and Herceptin as Neoadjuvant and Adjuvant Treatment in Patients with HER2-Positive Early Breast Cancer

  • Condition/Disease

    HER2-Positive Early Breast Cancer

  • Test Drug

    CT-P6

Participate Sites
7Sites

Terminated7Sites

2023-11-01 - 2026-12-31

Phase III

An Open Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of the Combination of Lasofoxifene and Abemaciclib to the Combination of Fulvestrant and Abemaciclib for the Treatment of Pre- and Postmenopausal Women and Men With Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

  • Condition/Disease

    Metastatic Breast Cancer

  • Test Drug

    Lasofoxifene

Participate Sites
7Sites

Recruiting7Sites

2017-03-01 - 2019-12-31

Phase III

A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast Cancer (TNBC)

  • Condition/Disease

    Triple Negative Breast Neoplasms

  • Test Drug

    Pembrolizumab (MK-3475) ；KEYTRUDA®/吉舒達®

Participate Sites
7Sites

Terminated7Sites

陳訓徹
Linkou Chang Gung Medical Foundation

Division of General Surgery

曾令民
Taipei Veterans General Hospital

Division of General Surgery

2017-07-26 - 2020-06-30

Phase III

A Randomized, Double-Blind, Phase III Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer - (KEYNOTE-355)

  • Condition/Disease

    Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer

  • Test Drug

    Pembrolizumab (MK-3475)

Participate Sites
6Sites

Terminated5Sites

Study ended1Sites

曾令民
Taipei Veterans General Hospital

Division of General Surgery

1 6 7 8 9 10 11
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB